echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Active Ingredient Products News > The Safety of N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide

    The Safety of N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide

    • Last Update: 2023-04-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide, also known as MK-8628, is an investigational drug developed by Merck & Co.
    for the treatment of various diseases, including cancer and viral infections.
    The safety of this compound is of utmost importance in the development and use of new drugs in the pharmaceutical industry.

    The safety of N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide has been studied extensively in preclinical and clinical trials.
    Preclinical studies involve testing the compound in laboratory animals to evaluate its safety and efficacy before proceeding to clinical trials in humans.
    These studies help identify any potential safety concerns or adverse effects of the drug.

    The results of preclinical studies on N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide have shown that it has a good safety profile and is well-tolerated in various animal models.
    The compound has demonstrated efficacy in reducing viral load and increasing immune cell counts in animals infected with HIV, and it has also shown promise in treating cancer in preclinical models.

    Clinical trials involve testing the drug in human subjects to further evaluate its safety and efficacy.
    These trials are conducted in three phases, with each phase designed to answer specific safety and efficacy questions about the drug.
    Phase 1 involves testing the safety of the drug in healthy volunteers, while phases 2 and 3 involve testing the safety and efficacy of the drug in patients with the targeted disease.

    The safety of N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide has been evaluated in clinical trials, and the results have been encouraging.
    The compound has been well-tolerated in these trials, with most adverse events being mild to moderate in severity.
    The most common adverse events reported have included nausea, diarrhea, and fatigue, which are typical of many chemotherapy drugs.

    In addition to its good safety profile, N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide has shown promising efficacy in treating cancer and viral infections.
    The compound has demonstrated activity against a wide range of cancer cells in vitro and in vivo, including cells from breast, ovarian, and pancreatic cancer.
    It has also shown activity against HIV in vitro and in vivo, making it a promising candidate for the treatment of HIV and AIDS.

    Overall, the safety of N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.